Hansa Biopharma AB: Hansa Biopharma announces positive reimb

LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained

Related Keywords

Sweden , Stockholm , Belgium , Jordan , Leuven , Region Flamande , Stephanie Kenney , Hansa Biopharma , Prnewswire Hansa Biopharma , Dirk Kuypers , Klaus Sindahl , Department Of Nephrology , University Hospitals Leuven , European Union , European Medicines Agency Ema Priority , Renal Transplantation Program , Vp Global Corporate Affairs , European Medicines Agency , Nasdaq Stockholm , Human Leukocyte Antigens , Product Characteristics , End Stage Renal Disease , Dial Transplant , Englj Med , Hansa , Iopharma , Nnounces , Positive , Reimbursement , Decision , Defirix , Mlifidase , Desensitization , Treatment , Ighly , Desensitized , Patients , Kidney , Transplantation ,